Announcements

Job offersmore »



Tweeting Growers

Top 5 - yesterday

  • No news has been published yesterday.

Top 5 - last week

Top 5 - last month

Exchange ratesmore »




Canada: Canopy Growth funds AIDS research project

The Canadian AIDS Society announced a first of its kind research program funded by Canopy Growth Corporation. The program is designed to provide up-to-date information on the current state of evidence and research pertaining to the use of cannabis for medical purposes and to build tools for healthcare professionals to allow them to confidently assess and prescribe cannabis to appropriate patients.

Funded over two years at $100,000 per year by Canopy Growth Corporation — and guided by a newly created Cannabis Research Task Force of experts in the field of cannabinoid medicine — the project aims to develop guidelines and recommendations regarding the medical use of cannabis for optimal wellness, quality of life and pain management.

“Our goal is to leverage our existing knowledge and expertise in both HIV and the use of cannabis for medical purposes to create a better quality of life for many Canadians facing debilitating health conditions — particularly in the area of chronic pain management,” said Gary Lacasse, Executive Director of the Canadian AIDS Society. “This project builds on a body of existing knowledge and research developed by CAS over several years.”

The Task Force will be addressing issues surrounding the current lack of information — for Canadian health care practitioners and ultimately for patients — regarding guidance on the use of cannabis for medical or therapeutic purposes. It is estimated that 10% of Canadian physicians have written an authorization for medical cannabis.

“We are confident that this partnership with the Canadian AIDS Society and the broad medical and social expertise of the Task Force will result in practical guidelines for the use of cannabis that can be applied to many medical conditions,” said Mark Zekulin, President, Canopy Growth Corporation. “We have dedicated a great deal of effort into physician education over the last three years and I feel confident that this work will create another valuable tool that Canadian healthcare professionals and Canadians alike can use when considering cannabis as a therapy..”

The Cannabis Research Task Force is expected to review the current state of research for the use of medical cannabis and develop a scope of work for evidence-based Canadian guidelines in such areas as treatment, contraindications, dosing, chronic pain, risk management and regulatory issues, among others.

For more information:
www.cdnaids.ca
www.canopygrowth.com

Publication date: 7/7/2017

 


 

Other news in this sector:

11/17/2017 CAN (BC): Should Delta get a share of lucrative pot bucks?
11/16/2017 Vancouver firm eyes Uruguayan MMJ market
11/16/2017 MedReleaf Australia receives cultivation license
11/16/2017 Jamaica: MMJ companies form alliance
11/16/2017 IBM wants British Columbia to track legal pot with blockchain tech
11/15/2017 Greece hopes to boost economy with MMJ
11/15/2017 Aurora Cannabis plans to take over CanniMed
11/15/2017 US (CA): Cannabis growers could face taxes on destroyed crops
11/14/2017 US (NV): Grower hits record-breaking THC & terpene profiles
11/14/2017 US (CA): Coachella City approves cannabis greenhouse facility
11/13/2017 Canada: Supreme commences production in new flowering rooms
11/10/2017 CAN (ON): Beleave to expand with 80,000 sq. ft. in Hamilton
11/10/2017 Macedonian MMJ grower invests in LED
11/9/2017 Academic research into HPS vs. LED for cannabis cultivation
11/8/2017 Maximizing cannabis yields using controlled environment technology
11/8/2017 US (OH): Provisional licenses for Level II marijuana cultivators
11/8/2017 US (ME): Marijuana grower develops mechanical farmhand
11/8/2017 CAN (QC): Aurora receives cultivation license for Pointe-Claire site
11/7/2017 Biotech company and UC Davis to unravel cannabis genomics
11/7/2017 "Strong increase in cannabis production with bubble oxygenation"